We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

No middle for the middleman

9 November 2006 By Robert Cyran

The $21bn merger has inspired talk of similar deals involving other drug middlemen. There s one problem. This looks like a replay of a disastrous wave of acquisitions the sector went through in the early 1990s.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)